新型病毒载体呼吸道黏膜疫苗在人源化模型中增强抗结核免疫
研究建立人源化小鼠结核模型,评估新型病毒载体结核疫苗经呼吸道黏膜或胃肠外途径接种的临床相关性。结果显示疫苗在人源化小鼠中激活T细胞,且仅呼吸道黏膜途径以人T细胞依赖方式显著减少类人肺结核结局。提示人源化小鼠可用于预测新型结核疫苗保护效力。
要点
- 人源化小鼠结核模型可模拟人类免疫遗传多样性与易感性。
- 病毒载体疫苗经呼吸道黏膜而非胃肠外途径显著减少类人肺结核结局。
- 该模型有望在大型昂贵人体试验前预测结核疫苗保护效力。
核心结论
- 人源化小鼠可用于预测新型结核疫苗或策略的保护效力,助力全球结核疫苗临床开发。
研究设计与样本
- 研究建立人源化小鼠结核模型系统,比较病毒载体疫苗经呼吸道黏膜或胃肠外途径接种的效果。
主要发现
- 病毒载体疫苗在人源化小鼠中激活T细胞,与人类受种者一致。
- 呼吸道黏膜途径而非胃肠外途径以人T细胞依赖方式显著减少类人肺结核结局。
临床怎么用
- 提示呼吸道黏膜途径可能是新型病毒载体结核疫苗的优先接种策略。
- 人源化小鼠模型可作为临床前疫苗效力预测工具,减少后期试验风险。
局限性
- 原文未报告样本量、效应值、置信区间或P值等具体数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The translation of preclinically promising novel tuberculosis vaccines to ultimate human applications has been challenged by the lack of animal models with an immune system equivalent to the human immune system in its genetic diversity and level of susceptibility to tuberculosis. METHODS: We have developed a humanized mice (Hu-mice) tuberculosis model system to investigate the clinical relevance of a novel virus-vectored (VV) tuberculosis vaccine administered via respiratory mucosal or parenteral route. RESULTS: We find that VV vaccine activates T cells in Hu-mice as it does in human vaccinees. The respiratory mucosal route for delivery of VV vaccine in Hu-mice, but not the parenteral route, significantly reduces the humanlike lung tuberculosis outcomes in a human T-cell-dependent manner. CONCLUSIONS: Our results suggest that the Hu-mouse can be used to predict the protective efficacy of novel tuberculosis vaccines/strategies before they proceed to large, expensive human trials. This new vaccine testing system will facilitate the global pace of clinical tuberculosis vaccine development.
引用
- Yao Y, Lai R, Afkhami S, et al. Enhancement of Antituberculosis Immunity in a Humanized Model System by a Novel Virus-Vectored Respiratory Mucosal Vaccine. J Infect Dis. 2017. PMID: 28531291. doi:10.1093/infdis/jix252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。